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Abstract Leukocytic infiltrates, particularly myeloid cells,
can stimulate an anti-tumor immune response, but more
often they stimulate tumor development, including promot-
ing invasion, tumor growth, angiogenesis, and metastasis.
Distinct myeloid phenotypes are being characterized that
have been shown to promote tumor growth, angiogenesis,
and metastasis. This review provides an overview of myeloid
differentiation and spotlights specific pro-tumorogenic
myeloid populations and their role in cancer progression.
Efforts to characterize these pro-tumorogenic myeloid cell
immunophenotypes may lead to novel targets for cancer
therapy.
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Abbreviations
BM Bone marrow
CMPs Common myeloid progenitors
DCs Dendritic cells
EPCs Endothelial progenitor cells
GCV Gancyclovir
GMPs Granulocyte/macrophage progenitors
HSCs Hematopoietic stem cells
MDPs Myeloid dendritic-cell progenitors
MDSCs Myeloid derived suppressor cells
MEPs Megakaryocyte/erythroid Progenitors
MISCs Myeloid immune suppressor cells
MPPs Multi-potent progenitor cells
TAMs Tumor associated macrophages
TEMs Tie2 expressing monocytes
Tregs Regulatory T cells
Introduction
Tumor cells actively interact with each other and the
surrounding interstitial tissue through cell-to-cell contacts
as well as by both releasing and responding to soluble
factors present in the tumor microenvironment. This
interaction results in the generation of a population of
non-malignant cells, collectively denoted as the “tumor
stroma”, that are uniquely primed to support growth and
metastasis of the malignant population [1, 2]. This “tumor-
educated” stroma thus exhibits a unique phenotype that
promotes the growth, invasion and metastasis of the
malignant population [3, 4].
In recent years increasing attention has been focused on
the role of the host inflammatory cells comprising the
microenvironment stroma [5]. Specifically, myeloid cells
are a major component of the inflammatory infiltrate
frequently seen in primary tumors [6, 7]. On one hand,
myeloid/macrophage cells play a key role in the immune
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recognition and immune inductive process or by releasing
regulatory molecules to stimulate lymphocyte functions [8].
As a component of the innate immune response, myeloid
cells activate dendritic cells and natural killer (NK) cells
that can initiate an anti-tumor response. Consistent with this
role, in some mouse experimental models, syngeneic
macrophages from tumor bearing mice inhibited melanoma
growth in nude mice more than control macrophages [9].
However, often in both mouse models and in patients, the
myeloid population can instead drive tumor progression by
promoting neovascularization, metastasis, and immunosup-
pression [4, 6, 7]. Especially in human breast and cervical
cancers, strong correlation has been observed between
tumor macrophage density, as stained by a CD68 antibody,
and aggressive phenotype [10–13]. However, in other types
of human cancers, the data are often conflicting [14]. In
some studies of human stomach, lung, and colorectal
tumors, the degree of staining with a single macrophage
marker, CD68, correlated with good prognosis [14, 15].
The reason for the discrepancy correlating CD68 macro-
phage density and prognosis is not understood but may be
related to the phenotype or nature of the different
populations of myeloid cells present in the tumor, since
CD68 stains mature macrophages but not all myeloid
populations.
Myeloid cells circulate in peripheral blood as monocytes,
which extravasate from the blood vessel to enter tissues
[16]. The blood monocytes are young cells that already
possess many of the functional capacities (migratory,
chemotactic, and phagocytic) evident in more differentiated
macrophages [17]. Extravasated monocytes can differenti-
ate within tissues over time to become macrophages. It has
been long appreciated that tissue macrophages display a
range of functional and morphological phenotypes [18].
More recently, it can be argued that monocytes represent
the circulating macrophage population and also exhibit
unique properties and surface antigen expression in
response to factors encountered while in circulation as well
as after migration into specific tissues [19]. This review will
address the role of myeloid cells in tumor growth and
progression with emphasis on evaluation of myeloid cell-
derived endothelium (tumor vasculogenesis) and will
evaluate a range of myeloid phenotypes implicated in these
processes.
Myeloid Differentiation
Early in hematopoiesis multipotent, self renewing hemato-
poietic stem cells (HSCs) give rise to the multi-potent
progenitor cells (MPPs) which can subsequently give rise to
the common myeloid progenitors (CMPs). CMPs differen-
tiate into macrophages and dendritic-cell progenitors
(MDPs), granulocyte/macrophage progenitors (GMPs),
megakaryocyte/erythroid Progenitors (MEPs), or basophile/
mast cells. MDPs give rise to monocytes and dendritic cells
(DCs), however, GMPs have the ability to differentiate into
monocytesandgranulocytes[16, 20–23]. Figure 1 provides a
schematic overview of this differentiation cascade and
known species-specific antigen expression profile.
One of the important genes which is expressed during
myeloid lineage differentiation is the PU.1 gene, an ETS
transcription factor [20, 23–26]. PU.1 is critical during both
B-lymphocyte and myeloid cell differentiation and its
impaired expression results in both lymphocyte and mono-
cyte/macrophage deficiency [23, 24]. Another important
factor involved in monocyte to macrophage differentiation
is the hematopoietic growth factor colony stimulating factor-
1 (CSF-1) (also known as CD115 and M-CSF). CSF-1 is the
ligand for CSF-1R (c-fms, M-CSFR) which is expressed on
monocytes, macrophages, and DCs. Mice deficient in CSF-1
or CSF-1R show dramatic reduction of blood monocytes
[27, 28]. Other important factors in differentiation of
myeloid cells include transcription factors such as IRF8, c-
myc, and c-myb [20, 27, 29].
Circulating immature myeloid cells, monocytes, are a
heterogeneous population which can be divided into
different subtypes based on their morphology and surface
markers (Fig. 1). The two major subsets of monocytes
include a short lived “inflammatory” and a long lived
“resident” monocyte [19, 30–32]. Whereas some antigens
such as CD11b [33] and CD163 [34, 35] have been
characterized on both circulating monocytes and tissue
macrophages, other phenotypic markers such as CD68
[36–38] (human) and F4/80 [39] (mouse) are restricted to
tissue macrophages and are absent from the circulating
myeloid (monocyte) populations [35]. The exact nature of
what determines the differentiation of MDPs into different
subsets such as inflammatory or resident monocytes is not
clear and requires further investigation.
“Inflammatory” monocytes are defined by their expres-
sion of Ly6c
+ CX3CR
low, CCR2
+, CD62L
+ (see Fig. 1),
and CD16
-CD14
high (only human) and are generated
directly from MDPs in bone marrow (BM). They can re-
circulate between peripheral blood and BM [17, 19, 30–32].
Once they enter the peripheral circulation, inflammatory
monocytes migrate into the inflamed tissues and presum-
ably become “inflammatory” (i.e. M1) macrophages and
DCs in the presence of inflammatory chemokines to further
activate immune response [16, 17, 32, 40]. High level
expression of CCR2 and CD62L, which are receptors for
the chemokine MCP-1/CCL2 by monocytes, facilitates the
appropriate homing to injured tissue [19, 41–43].
The second major population of monocytes, “resident”
monocytes, are characterized by a number of markers such
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high, Ly6c
-, CCR2
-, CD62L
- (murine and
human), CD16
+, CD14
+ (mainly in human) [16–18, 31,
32, 44, 45]. Resident monocytes home to non-inflamed
tissues such as to liver, lung, brain, and spleen to comprise
the resident macrophage population. They can also circulate
in the peripheral blood and participate in the resolution of
inflammation, wound healing, or in the removal of cell
debris [16, 31, 40, 46, 47]. These populations of monocytes
migrate into tissues as a result of high level expression of
CX3CR1, which is the receptor of CX3CL1 ligand, a
highly expressed transmembrane chemokine in endothelial
cells [19, 48]. It is not clear how the classification of
monocytes and macrophages into resident and inflammatory
subpopulations relate to the generation of the specific
myeloid subpopulations described in this review, such as
Tie2-expressing monocytes (TEMs) or myeloid derived
suppressor cells (MDSCs). In the following sections, we
will discuss recent characterizations of both immature and
mature myeloid subpopulations linked to specific immuno-
logical and physiological function that lead to tumor
promotion (Fig. 2).
Myeloid Phenotypes and Tumor Progression
Tumor Associated Macrophages (TAMs)
The “TAMs” nomenclature broadly denotes the tumor-
associated macrophage population. Studies to quantify
TAM density in various malignancies have almost exclu-
sively utilized the markers CD68 (human) or F4/80
(mouse). Many human studies have shown a positive
correlation between tumor macrophage density and blood
vessel density [12, 49, 50]. The mechanism(s) by which
TAMs are believed to play a role in angiogenesis is
primarily by secreting proangiogenic factors, such as
VEGF-A, VEGF-C, and bFGF [51]. Expression of these
genes by macrophages in tumors is regulated, at least in
part, by hypoxia-mediated upregulation of transcription
factors such as HIF1α and HIF-2α [49, 52]. In addition
macrophages secrete many proteases including MMP-2,
MMP-7, MMP-9, and MMP-12, that can support neoangio-
genesis by facilitating matrix turnover [53, 54]. Matrix
degradation enhances bioavailability of matrix-bound growth
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Fig. 1 Scheme of hematopoietic lineage differentiation. Depiction of the
stages of myelopoiesis and associated surface antigen expression.
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areas [55]. In addition to this proangiogenic function, it is
hypothesized that TAMs serve as immunosuppressive cells
to facilitate tumor evasion of the host immune system [56,
57]. Compared to thioglycolate-elicited peritoneal macro-
phages, TAMs secrete less interleukin (IL)-12 and other
inflammatory cytokines and more immunosuppressive IL-10
[56]. As peritoneal, thioglycolate-stimulated macrophages
were used for these comparative studies, it is not clear if the
less inflammatory chemokine profile of TAMs is unique to
tumors and distinct from other, non-malignant tissue- or
wound- associated macrophages [56, 57].
Two major functional states have been described for
tissue macrophages and named as M1 and M2 [58]. M1
macrophages represent classically activated macrophages
that are induced by interferon-γ alone or in combination
with lipopolysaccharide and tumor necrosis factor-α [59].
M1 macrophages produce high levels of inducible nitric
oxide synthase and pro-inflammatory cytokines, such as
IL-12, and are generally considered as part of the inflamma-
tory response, such as seen in infection [59–61]. In contrast,
glucocortigoids, IL-4, IL-13 and IL-10 induce a distinct M2
macrophage phenotype that express arginase I and EGF,
promote angiogenesis, favor tissue remodeling and invasion,
and are able to inhibit the inflammatory response through the
secretion of IL-10 [59, 60, 62]. Thus M2 macrophages
would be hypothesized to exert a tumor-promoting activity
by inhibiting the host immune response. Since a high density
of CD68
+, intra-tumoral macrophages are associated with
poor prognosis in a number of human tumors (i.e. cervix,
and breast [63][ 64], this association, in conjunction with the
reported “anti-inflammatory” cytokine array profile of
macrophages isolated from mouse tumors (i.e. IL-4, IL-13,
etc.), are used to support the hypothesis that TAMs represent
an M2-polarized macrophage [60]. Many studies have
performed partial characterizations of TAMs, such as by
showing the absence of macrophage NOS staining, to further
support a predominant M2 phenotype [60]. However,
aspects such as decreased expression of NOS, are also
attributed to MDSCs [65, 66]. Moreover, it is not clear if a
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Fig. 2 Schematic of interactions between tumor and bone marrow
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from other tissue resident macrophages. This is relevant
since, unlike TAMs, tissue resident macrophages do not play
an active role in promoting angiogenesis or secreting matrix
proteases. As we gain greater understanding of tumor
associated myeloid phenotypes, the M1 and M2 designations
will likely be further refined.
Myeloid Derived Suppressor Cells (MDSCs)
MDSCs (also known as myeloid immune suppressor cells,
MISCs) are a myeloid population which are significantly
increased in the spleen and BM of tumor-bearing mice or in
peripheral circulation of cancer patients and inhibit host
immune function [65–67]. In mice, MDSCs express CD11b
and Gr-1 [65]. CD11b is expressed by both circulating
immature myeloid cells such as monocytes as well as
macrophages (Fig. 1). Gr-1 is a murine specific antibody
that recognizes both Ly-6G, expressed only on granulo-
cytes, and Ly-6C, expressed on myeloid cells as well as
some NK cells [65]. Evaluation of GR-1
+ MDSCs using
antibodies that distinguish between Ly-6C and Ly-6G have
identified two MDSC subsets: Co-expression of CD11b and
Ly-6G
+/Ly-6C
high identify primarily monocytic lineage
cells whereas CD11b and Ly-6G
+/Ly-6C
low identify gran-
ulocytic lineage cells [65, 68]. Both subsets are increased in
mice harboring tumors, although the larger increase was
observed in the granulocytic subset [68]. In mouse tumor
models, the levels of MDSCs in spleen and peripheral
circulation appear to increase substantially in the presence
of tumor to levels often greater than 50% [65]. However,
within tumors MDSCs constitute a modest portion of the
leukocyte population within tumors (<5%) [69].
In humans, “MDSC” populations have been reported on
the basis of their ability to mediate immune suppression
using a variety of different markers such as CD11b
+/CD14
-,
only as CD14
+, or CD34
+, although studies have also
described a CD14
+/HLA-DR
-/low population [70–72]. The
murine MDSC markers, CD11b
+/Gr-1
+, are present on both
immature (monocyte) and mature (macrophage) popula-
tions and have been studied in the context of both
peripheral circulation as well as associated with tumor
tissue. By contrast, human “MDSCs” are characterized by
more immature markers and, hence, have been enumerated
primarily in peripheral blood of cancer patients [70–72].
The diversity of circulating MDSC phenotype in humans
suggests that a assorted population of myeloid cells may
exhibit immune inhibitory functions and that the immune-
inhibitory phenotype is likely to be driven by interplay
between host and tumor-derived signals [65, 67].
The CD11b
+/Gr-1
+ murine MDSCs were initially de-
fined by their ability to suppress the immune system
through multiple immune effectors, including direct mod-
ulation of T cells and NK cell activation and also by
inducing regulatory T cells (Tregs) through a number of
mechanisms [73, 74]. Important factors that contribute to
the suppressive activity of MDSCs are production of high
levels of reactive oxygen species and peroxynitrite, both of
which suppress T cell function [75]. Interestingly, blocking
MDSC-derived reactive oxygen species led to their differ-
entiation into macrophages and dendritic cells, suggesting
that this may be a mechanism by which to target MDSCs
[75]. Another potential method of MDSC-mediated T cell
suppression is through the high intracellular expression of
arginase, which causes a reduction in arginine used in Tcell
activation [72, 76, 77]. MDSCs also activate NOS and
together with arginase, can generate superoxides that also
facilitate T cell apoptosis [78]. Such effects on T cells serve
to suppress anti-tumor immunity and also modulate the
behavior of antigen presenting cells (DCs and macro-
phages) [79]. Moreover, treatment of tumor bearing mice
with anti GR-1 antibody (which recognize both MDSCs
and neutrophils) resulted in delayed tumor growth, provid-
ing tantalizing data to further explore the effect of targeting
MDSCs for tumor therapy [80].
MDSCs may also play a broader role inmodulating tumor-
related inflammation. MDSCs modulate cytokine production
of macrophages, skewing them towards decreased production
of IL-12, potentially through Toll-like receptor 4 signaling
[81]. Gr-1
+ myeloid populations were also found to promote
tumor angiogenesis by expressing MMP-9 and VEGF and
play a role in the angiogenic switch leading to the
development of islet carcinoma [82]. More recently, direct
incorporation of CD11b
+/Gr-1
+ cells into vascular endothe-
lium were reported when such cells were admixed with
tumor cells prior to implantation, albeit the frequency of
endothelial differentiation of MDSCs was not reported [69].
Currently, the majority of studies addressing the immuno-
suppressive function of MDSCs utilize splenic or peripheral
blood-derived cells obtained from tumor-bearing mice [65]. It
is not clear if MDSCs within tumors function similarly as
immune-suppressive cells. More studies are needed to
confirm and further understand changes in surface phenotype
and/or function of murine MDSCs once they are recruited to
the tumor. It will also be important to clarify and further
characterize the human MDSCs and define if the aspects
attributed to murine CD11b
+/Gr-1
+ MDSCs are relevant to
human cancers.
Vascular Leukocytes/Myeloid-Endothelial Biphenotypic
Cells
Myeloid Plasticity
Several groups, including our own, have shown that
circulating human or mouse monocytes can be induced in
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(CD156), flk-1(VEGFR2/KDR), von Willebrand Factor
(vWF), tie2, and endothelial lectins] and an endothelial
phenotype (network formation, synthesis of eNOS, and
Weibel Palade bodies) [83–86]. Although this population
shows limited proliferative potential, these cells can home
to sites of ischemia and tumor where they demonstrate
significant proangiogenic effects [87]. Importantly, they are
also capable, at modest levels, of incorporating into
functional neovasculature, i.e., vasculogenesis [87–89]. In
fact, many studies attempting to generate and/or measure
endothelial progenitor cells (EPCs) have utilized short term
adhesion of mononuclear cells to fibronectin-coated dishes
which primarily selects for endothelial differentiation of
circulating monocytes [90]. In vitro culture of monocytes in
endothelial promoting media initially generated cells that
co-expressed both endothelial and myeloid markers [85].
Upon prolonged culture (>30 d), hematopoietic and myeloid
marker expression were eventually downregulated but endo-
thelial antigen expression was retained in culture [85].
Additionally, myeloid to endothelial plasticity has also
been demonstrated in vivo in several preclinical models.
Specifically, adoptive transfer of highly enriched immature
myeloid progenitors resulted in these myeloid cell-derived
blood vessels in the recipient liver [91]. Monocyte-derived
endothelial-like cells were shown to engraft in tumor
vessels in low numbers. Vascular plasticity of myeloid
cells has been also described during ischemic injury in
murine hearts overexpressing the chemokine MCP-1/CCL2
[92], as well as in other contexts. Goodell and colleagues,
for example, showed that myofibers generated in an inflam-
matory nidus can be derived at low levels from hematopoietic
transdifferentiation and that this occurs through a myeloid
intermediate [93]. Two other independent studies show that
myeloid progenitors transdifferentiate into lymphatic endo-
thelial cells in inflammatory/repair tissues [94, 95].
To better define if endothelial differentiation from
myeloid progenitors occurred more efficiently from mature
versus immature myeloid progenitors, our group used
various myeloid populations isolated from transgenic mice
that expressed lacZ under the control of an endothelial cell
promoter [85]. These data supported that myeloid to
endothelial differentiation occurred with ∼4-fold greater
efficiency from early myeloid progenitors, not differentiated
progeny such as macrophages [85]. Adoptive transfer studies
using a different model system also further supported the
notion that more immature myeloid progenitors made a
greater contribution to host hepatic vasculature [91].
Vascular Leukocytes in Tumors
Although a growing body of data (as discussed above)
showed that cultured monocytes can be induced to co-
express myeloid and endothelial antigens, evidence for the
existence of a myeloid/endothelial biphenotypic population
(also called vascular leukocytes) in vivo was introduced
more recently during evaluation of both mouse and human
ovarian cancer tissue. A tumor associated CD11c
+ myeloid
population was identified that co-expressed endothelial
markers, P1H12 and VE-cadherin, in murine ovarian
cancers [69, 96]. Myeloid/endothelial biphenotypic popula-
tions were also identified in murine sarcoma and melanomas
that comprised around 2-5% of tumor-associated leukocytes
[85]. In this study vascular leukocytes were not detected in
normal mouse or human peripheral blood or bone marrow.
This suggests that the biphenotypic cell may not be part of
the normal differentiation cascade of the hematopoietic
progenitor but may be generated from vascular leukocytes
(e.g. myeloid cells) present at the tumor site by specific
local cues [85]. In analysis of 10 consecutive advanced
stage human ovarian cancers, similar populations of
biphenotypic cells co-expressing CD14 monocyte marker
and multiple endothelial markers were also identified to
comprise 52% of tumor-associated leukocytes (CD45
+
cells) [69, 96].
Isolated vascular leukocytes from mouse and human
tumor tissue were capable of generating functional vessels
when reimplanted in vivo within matrigel plugs [97].
However, it is unclear the extent of contribution of vascular
leukocytes to functional, in situ tumor vasculature [97, 98].
Co-localization of myeloid markers with functional vessels
as well as increased frequency of bone marrow derived
vessels under conditions that were shown to increase
vascular leukocytes (such as increased VEGF or TNF-α)
have been reported in tumors, however, the relative direct
contribution of vascular leukocytes to tumor vasculature is
unknown but suspected to be very low [97, 98]. In one
study, the level of myeloid cell-derived tumor vasculature
was found to be dependent of the type of tumor, present in
lewis lung carcinoma-derived tumors but absent in mouse
melanoma, despite the fact that relatively similar levels of
microvasculature was evident [99]. Moreover, it was found
that site specific expression of stromal derived factor-1α
(SDF-1α/CXCL12a) was necessary for neovasculogenesis
from myeloid cells in tumors [99]. Despite low direct
contribution to vasculature, vascular leukocytes represent a
myeloid population that promotes tumor growth. Admixing
myeloid cells with tumors under conditions that promote
generation of vascular leukocytes (ie VEGF or TNF-α
expressing tumors) resulted in larger, highly vascularized
tumors [97, 98]. In addition to their significant contribution
to tumor angiogenesis as well as some impact on tumor
vasculogenesis, it will be important to investigate if this
population, like MDSCs, also exhibit immunosuppressive
attributes as well as elucidate the mechanism by which
vascular leukocytes promote tumor growth and vascularity.
6 P.P. Young et al.Tie2 Expressing Monocytes (TEMs)
A small (1-4%) population of CD11b
+ cells expressing
Tie2, an endothelial enriched gene encoding angiopoietin
receptor tyrosine kinase, were identified in mouse mammary
tumors [100, 101]. These were named Tie2 expressing
monocytes (TEMs), in part because they were initially
characterized as expressing CD11b
+, a marker present on
circulating monocytes (though CD11b can also be present on
differentiated macrophages, see Fig. 1)[ 65, 101, 102]. The
monocyte nomenclature suggests that these cells represent an
immature myeloid lineage, which is supported by the fact
that CD11b
+/Tie2
+ TEMs were also identified in the
peripheral circulation of both human and mice [103].
Enriched populations of peripheral blood-derived TEMs
exhibited proangiogenic properties in a matrigel plug assay,
albeit these cells were not compared directly with a myeloid-
enriched population depleted of TEMS but instead to
peripheral blood mononuclear cells (which would contain
large numbers of lymphocytes, some granulocytes as well as
myeloid cells) depleted of TEMs [101]. In a more recent
study, TEMs isolated directly from mouse mammary tumors
were characterized to express similar levels of F4/80 antigen
as TAMs, suggesting that TEMs isolated from the tumor
tissue itself may represent a well-differentiated myeloid
(macrophage) population [104]. Moreover, it is not known if
circulating TEMs exhibit a distinct functional phenotype
from tumor-associated TEMs [104].
TEMs were uniquely enriched in the tumor periphery in
association with blood vessels in mouse tumors [69, 96,
101]. Despite their low abundance in comparison to the
total tumor myeloid population, TEMs displayed a striking
proangiogenic phenotype when compared to CD11b
+/Tie2
-
population [100]. Selective ablation of TEMS in mouse
LLC, glioma, mammary [101, 105] with a suicide gene
induced by the drug gancyclovir (GCV) at the time of
tumor implantation resulted in ∼2-fold delayed growth and
significantly reduced angiogenesis [105]. Importantly,
despite expression of an endothelial marker, Tie2, murine
tumor-derived TEMs were shown by extensive genomic
characterization to differ markedly from endothelial cells
and from CD11b
+/Gr-1
+ (MDSCs) derived from spleen, but
to be similar to TAMs [104]. The differences identified
between MDSCs and TEMs may reflect that splenic,
instead of tumor-associated, MDSCs were used for the
comparative analysis [104]. It is likely, that myeloid
populations isolated from peripheral blood or spleen repre-
sent a more immature cell type than ones isolated from
tumor tissue suspensions. However, the lack of antigenic and
genomic overlap between endothelial cells and TEMs
combined with the clear similarities between TEMs and
other myeloid and hematopoietic cells suggest that TEMs,
unlike vascular leukocytes, are unlikely to undergo trans-
differentiation into endothelial cells [69, 96]. In fact,
although TEMs were found closely associated with tumor
vasculature, evidence of direct contribution to vessel
endothelium was absent [69, 96]. These data are further
supported by our study which identified TNF-α as an
important tumor-derived factor that enhance tumor-
associated vascular leukocytes by promoting in situ differ-
entiation of endothelial differentiation of myeloid cells [98].
Importantly, TNF-α did not increase tumor associated
CD11b
+/Tie2
+ or F4/80
+/Tie2
+ TEMs.
Myeloid Educating and Recruiting Signals
Circulating blood monocytes are recruited to the tumor by a
range of growth factors and chemokines, often produced by
the tumors themselves [106]. Other inflammatory cells,
such as B lymphocytes, have been implicated in producing
trophic factors that promote macrophage recruitment [107].
Following recruitment, it is widely accepted that the tumor/
myeloid cell crosstalk (Fig. 2) educate recruited myeloid
cells towards a tumor-promoting phenotype(s), although the
nature of these phenotypes is not completely understood
[5, 108]. Understanding the mechanisms by which pro-
tumorogenic, myeloid immunophenotypes are generated
either in circulation or within the tumor milieu can be used
to develop novel anti-tumor therapy [108]. Hence, this area
of study is on the forefront of cancer research [108]. While
a number of factors have been identified that recruit
myeloid cells to tumor sites (i.e., VEGF, PlGF, MCP-1/
CCL2, SDF-1α/CXCL12a, and β-defensins) [109], there is
much less known about tumor-derived signals that modu-
late the generation of unique myeloid subtypes during
cancer growth. Tumor-derived VEGF and TNF-α have
been shown to increase in situ differentiation of tumor-
associated vascular leukocytes [97, 98]. It is suggested that
the complement of cytokines (high IL-4, 10 and 13) may
skew the TAM population to an M2 phenotype [110]. A
recent study has shown that IL-4 and IL-13, especially
derived from Th2-polarized CD4
+ T lymphocytes, promote
some aspects of the M2-type immunosuppressive pheno-
type in a context-dependent manner [62]. Other aspects of
the M2 immunosuppressive phenotype may be regulated by
NF-kB signaling whereas the proangiogenic properties of
the M2 TAMs are regulated by other signals [111]. Other
unique myeloid populations, such as TEMs and MDSCs,
are thought to be present in the circulation and get recruited
to the tumor site [66, 101, 112]. Many factors, such as
VEGF, have been implicated with accumulation of several
myeloid subtypes [4, 97]. Increased TEM density was
found in association with tumor hypoxia and Ang2
secretion [100]. Many proinflammatory factors (i.e. VEGF,
GM-CSF, IL-1b, IL-6, and S-100 proteins) were associated
with increased circulating MDSCs [66]. More studies are
Myeloid Cells in Cancer Progression: Unique Subtypes and Their Roles 7needed to understand how tumor/host crosstalk generates
both systemic and local signals that enhance specific
myeloid subtypes.
Conclusion
TAMs, MDSCs, TEMs and vascular leukocytes are
myeloid populations implicated in promoting tumor pro-
gression (Fig. 2). Although each of these myeloid sub-
populations demonstrates some characteristic phenotype/
antigen profile, these subpopulations also display signifi-
c a n td i v e r s i t yi nf u n c t i o na n dc h a r a c t e r i z a t i o na m o n g
different model systems and likely represent a heteroge-
neous population. Human MDSCs, as an example, have
been characterized with different sets of surface markers
[70–72]. In different tumor models MDSCs mediate
immune suppression by distinct mechanisms [65]. More-
over, there is a great deal of overlap in the pro-angiogenic
and/or immunosuppressive functions of most of these
myeloid subtypes. For example, in addition to vascular
leukocytes, one study suggests that MDSCs may also be
capable of contributing to blood vessels by endothelial
differentiation [69]. The role of myeloid cells as an
“endothelial progenitor cell (EPC)” remains controversial;
both additional data and elucidation of the impact of
myeloid-derived endothelium to tumor growth and progres-
sion are needed. Future studies to better characterize and
define the functional roles of these protumorogenic myeloid
subsets will hopefully elucidate the complex biology of
myeloid cells during tumor progression.
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